Creating new treatments for drug-resistant infections and emerging diseases
Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases
This study is working on new treatments for tough infections caused by drug-resistant bacteria, like Pseudomonas aeruginosa, to help patients who struggle with these hard-to-treat illnesses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Revagenix, INC. NIH-funded |
| Lab location | 1 site (San Mateo, United States) |
| Project ID | NIH-11047618 on NIH RePORTER |
What this research studies
This research focuses on developing new therapeutic products aimed at combating biodefense pathogens and emerging infectious diseases, particularly those caused by drug-resistant bacteria like Pseudomonas aeruginosa. The approach includes optimizing potential drug candidates, conducting preclinical studies, and preparing for clinical trials to ensure safety and effectiveness. Patients may benefit from innovative treatments that could address infections that are currently difficult to treat due to antibiotic resistance.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals suffering from infections caused by drug-resistant bacteria or those at risk of emerging infectious diseases.
Not a fit: Patients with infections that are not caused by drug-resistant bacteria or those not affected by emerging infectious diseases may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat infections resistant to current antibiotics.
How similar studies have performed: Other research has shown promise in developing treatments for drug-resistant infections, indicating that this approach has potential for success.
Where this research is happening
San Mateo, United States
- Revagenix, INC. — San Mateo, United States (Active)
Researchers
- Principal investigator: Cirz, Ryan — Revagenix, INC.
- Study coordinator: Cirz, Ryan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.